Featured Clinical Trials
Learn what’s coming down the research pipeline, and find breast cancer clinical trials you may be eligible to participate in.
The phase II HERMIONE study is designed to compare MM-302, a new anti-HER2 medicine, plus trastuzumab, to chemotherapy of a physician’s choice, plus trastuzumab.
Researchers seek 600 men or postmenopausal women who have hormone receptor-positive, HER2-negative breast cancer that has spread to tissue, lymph nodes or another area of the body for a phase III study.
Adults with metastatic or locally advanced breast cancer and a BRCA1 or BRCA2 mutation are in demand – three clinical trials, EMBRACA, OlympiAD and BRAVO are testing different PARP inhibitors for safety and effectiveness.
Researchers seek 910 women or men with stage IIIC or stage IV breast cancer for a phase III study. The trial will include people starting treatment for the first time as well as those who had previous treatment that didn’t work or stopped working.
Researchers seek 500 women who have hormone receptor-positive, HER2-negative advanced breast cancer to take part in a phase III study testing a new medicine pair. Women who are postmenopausal, or no longer get their periods, may qualify to enroll in the study if they have not yet received treatment for advanced breast cancer.
Researchers seek 306 people with metastatic, HER2-negative breast cancer and who tested positive for either a BRCA1 or BRCA2 mutation to take part in a treatment study. The trial team will assess the survival benefit and safety of niraparib, an oral PARP inhibitor, compared with physicians’ choice of standard chemotherapy.
Researchers seek 880 men and women with metastatic breast cancer who have a primary tumor still in the breast for a study designed to find out if removing it lengthens survival. The primary tumor is the first tumor in the breast. Cancer cells from the primary tumor can spread to other parts of the body, causing metastatic disease.
Researchers from the National Surgical Breast and Bowel Project seek women with early-stage, HER2-low breast cancer for a phase III study. The trial team is exploring whether adding trastuzumab (Herceptin) to combination chemotherapy improves invasive disease-free survival.
Researchers seek participants with early-stage, HER2-positive breast cancer for a phase III study. The trial team will explore which of two anti-HER2 medicines results in the longest invasive disease-free survival.
Researchers seek 48 women for a small, phase IB study of ONT-380, a new anti-HER2 medicine that can be taken by mouth. The pill will be given along with the standard amount of T-DM1, by vein.